Bahia Grass Allergy: Florida's Second Sour Grass That Immunotherapy Misses

Bahia grass (Paspalum notatum) is a warm-season grass native to Brazil that was introduced to Florida and the Gulf Coast for erosion control and pasture use and has since naturalized across the entire subtropical region. It is now the dominant grass on Florida roadsides, highway medians, rural pastures, and residential lawns. Bahia's major allergen Pas n 1 is a Group 1 beta-expansin protein that was identified as the most frequently recognized grass pollen allergen in a Texas study, indicating high prevalence of sensitization in subtropical US populations. Florida's warm, humid climate allows bahia to produce pollen from April through October, creating a seven-month exposure window that sustains IgE sensitization and seasonal symptoms throughout the warm months.

If your grass allergy symptoms persist in Florida despite Grastek, Oralair, or standard grass SCIT, bahia grass sensitization is a likely explanation. Bahia belongs to subfamily Panicoideae and completely lacks Group 5 allergens — the cross-reactivity proteins that allow a single timothy-based immunotherapy to cover all Pooideae grasses. Bahia's Pas n 1 allergen is immunologically independent from both Pooideae and bermuda (Chloridoideae) allergens. Florida nasal provocation studies confirmed absent clinical cross-reactivity with timothy. If your current grass immunotherapy contains only Pooideae or bermuda extracts, it provides no protection against your bahia sensitization. A Pas n 1 specific IgE test or skin prick test with bahia extract can confirm this diagnosis and redirect your treatment.

Yes, simultaneous bermuda and bahia sensitization is well-documented in Florida and Gulf Coast patients and represents a particularly complex grass allergy presentation. Bermuda (Cynodon dactylon, subfamily Chloridoideae) and bahia (Paspalum notatum, subfamily Panicoideae) are from different sour grass subfamilies with limited cross-reactivity between them — meaning separate Cyn d 1 and Pas n 1 specific IgE populations drive each sensitization independently. The clinical implication is that effective immunotherapy requires a bermuda extract (Cyn d 1) and a bahia extract (Pas n 1) as separate components. Add in Pooideae sensitization (Phl p 5), and a triple-sensitized Florida patient needs three distinct immunotherapy extracts — the most complex grass allergy regimen encountered anywhere in the United States.

Bahia grass is recognizable by its distinctive reproductive structure: two seed-bearing branches that extend from the top of each seed stalk, forming a V-shape or Y-shape that is visible from a distance on unmowed lawns, roadsides, and highway medians. In Florida, these V-shaped seed heads are ubiquitous from spring through fall. The grass itself has a medium texture and grows in dense, low mats. Highway medians throughout Florida, particularly along Interstate 4, Interstate 75, and US highway corridors, are largely maintained in bahia grass, creating unavoidable pollen exposure for commuters during peak production months. When you see these distinctive seed heads on your drive to work in May or June, bahia pollen counts are elevated.

Yes, bahia grass specific IgE can be measured using ImmunoCAP g17 (Paspalum notatum), and skin prick testing with non-standardized bahia extract is available at allergy clinics familiar with Florida grass allergens. Unlike the FDA-standardized extracts for timothy (g6), bermuda (g2), and six other grasses (all at 100,000 BAU/mL, or 10,000 BAU/mL for bermuda), bahia has no standardized extract, making both testing and treatment less precise than for standardized allergens. The test must be specifically requested — most standard allergy panels in practices outside Florida do not include bahia. If you have Florida grass allergy symptoms that have not responded to standard grass testing and treatment, ask your allergist specifically about bahia testing.

Bahia pollen season in Florida runs from approximately April through October, with peak production from June through August when warm subtropical temperatures support maximum grass growth and seed-head production. This seven-month season overlaps substantially with bermuda's March through November season, creating a combined warm-season grass pollen burden that extends for most of the year in Florida. In South Florida, the warm subtropical climate may extend bahia pollen production into November in some years. Florida commuters are particularly exposed because highway medians and roadsides throughout the state are maintained in bahia grass, creating a pollen exposure vector that cannot be avoided through residential lawn management alone.

Triple grass sensitization refers to simultaneous IgE responses to Pooideae grasses (such as timothy, detected by Phl p 5), bermuda grass (Chloridoideae, detected by Cyn d 1), and bahia grass (Panicoideae, detected by Pas n 1) — three immunologically independent sensitizations documented in Florida and Gulf Coast populations. Treatment requires three separate immunotherapy extracts because no cross-reactivity exists between these subfamilies. SCIT management traditionally uses separate vials for each sensitization, requiring weekly injections from multiple vials. Custom SLIT drops can compound all three extracts into a single daily home regimen, which is substantially more practical for patients who must maintain treatment over 3 to 5 years. Confirming triple sensitization requires a comprehensive panel specifically requesting all three grass component tests.

Yes, bahia grass allergy can be treated with allergen-specific immunotherapy using Paspalum notatum extract, though this requires non-standardized extract since no FDA-standardized bahia product exists. Custom-compounded sublingual immunotherapy drops containing bahia extract are the most accessible option for most patients, as they can be formulated to include bahia alongside any concurrent grass and non-grass sensitizations in a single daily home regimen. Subcutaneous immunotherapy with non-standardized bahia extract is also available from allergy practices with Florida experience, placed in a separate vial from Pooideae and bermuda extracts. The allergen-specific immunotherapy mechanism — progressive immune tolerance induction through repeated low-dose allergen exposure — applies to bahia as to any major grass allergen, and significant symptom reduction is expected over 3 to 5 years of consistent treatment.

Bahia grass allergy is not inherently more severe than bermuda or timothy sensitization in terms of symptom intensity per unit of pollen exposure. However, bahia presents unique challenges that make it more difficult to manage in practice. First, it is the most diagnostically underserved major US grass allergen, with no FDA-standardized extract, absent from most routine panels, and unfamiliar to many allergists outside Florida. Second, it is immunologically independent from both Pooideae and bermuda, meaning standard grass immunotherapy provides no benefit. Third, its seven-month subtropical season creates sustained allergen exposure that exceeds most Pooideae grass seasons. The combination of diagnostic obscurity, therapeutic gaps, and prolonged exposure makes bahia one of the most challenging grass allergens to manage in US clinical practice.

Florida and Gulf Coast patients sensitized to bahia frequently have concurrent sensitizations to bermuda grass (the other major sour grass of the region), Pooideae grasses (including any cool-season grass exposure), and ragweed (which peaks in September and October, overlapping with the tail end of bahia season). The subtropical Florida environment also supports year-round mold growth, and Alternaria and Cladosporium sensitization is common in patients with chronic warm-season respiratory symptoms. Additionally, grass pollen profilin cross-reactivity (from Pas n 1-related profilins) may produce oral allergy syndrome symptoms with raw tomatoes, melons, and other profilin-rich foods in a subset of sensitized patients. A comprehensive allergy evaluation in a Florida patient should address all of these concurrent sensitizations to fully characterize the allergen burden.